Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-CON-02 in HER2-positive Metastatic Breast Cancer
NCT03062007Phase 1Terminated
- Sponsor
- BioIntegrator LLC
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab conjugate in breast cancer, sponsored by BioIntegrator LLC. Primary endpoints: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) and Maximum tolerated dose (MTD) or recommended dose (RD). Started Sep 2016; status: terminated.
02
Drugs
trastuzumab conjugate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03062007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03062007.